Supernus Pharmaceuticals Inc (SUPN)
35.47
+0.71
(+2.04%)
USD |
NASDAQ |
Nov 05, 14:48
Supernus Pharmaceuticals Enterprise Value: 1.568B for Nov. 4, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2024 | 1.568B |
| November 01, 2024 | 1.525B |
| October 31, 2024 | 1.530B |
| October 30, 2024 | 1.574B |
| October 29, 2024 | 1.547B |
| October 28, 2024 | 1.535B |
| October 25, 2024 | 1.523B |
| October 24, 2024 | 1.515B |
| October 23, 2024 | 1.519B |
| October 22, 2024 | 1.510B |
| October 21, 2024 | 1.508B |
| October 18, 2024 | 1.556B |
| October 17, 2024 | 1.518B |
| October 16, 2024 | 1.525B |
| October 15, 2024 | 1.500B |
| October 14, 2024 | 1.467B |
| October 11, 2024 | 1.471B |
| October 10, 2024 | 1.410B |
| October 09, 2024 | 1.437B |
| October 08, 2024 | 1.444B |
| October 07, 2024 | 1.419B |
| October 04, 2024 | 1.417B |
| October 03, 2024 | 1.422B |
| October 02, 2024 | 1.425B |
| October 01, 2024 | 1.416B |
| Date | Value |
|---|---|
| September 30, 2024 | 1.371B |
| September 27, 2024 | 1.347B |
| September 26, 2024 | 1.348B |
| September 25, 2024 | 1.303B |
| September 24, 2024 | 1.337B |
| September 23, 2024 | 1.384B |
| September 20, 2024 | 1.406B |
| September 19, 2024 | 1.423B |
| September 18, 2024 | 1.407B |
| September 17, 2024 | 1.401B |
| September 16, 2024 | 1.388B |
| September 13, 2024 | 1.367B |
| September 12, 2024 | 1.356B |
| September 11, 2024 | 1.365B |
| September 10, 2024 | 1.498B |
| September 09, 2024 | 1.521B |
| September 06, 2024 | 1.518B |
| September 05, 2024 | 1.547B |
| September 04, 2024 | 1.582B |
| September 03, 2024 | 1.566B |
| August 30, 2024 | 1.590B |
| August 29, 2024 | 1.582B |
| August 28, 2024 | 1.562B |
| August 27, 2024 | 1.576B |
| August 26, 2024 | 1.574B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
757.21M
Minimum
Mar 18 2020
2.362B
Maximum
Apr 21 2023
1.486B
Average
1.460B
Median
Jul 05 2023
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals Inc | 1.924B |
| Regeneron Pharmaceuticals Inc | 83.27B |
| United Therapeutics Corp | 13.90B |
| Ligand Pharmaceuticals Inc | 1.785B |
| Myomo Inc | 106.78M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 19.92M |
| Revenue (Quarterly) | 168.32M |
| Total Expenses (Quarterly) | 150.11M |
| EPS Diluted (Quarterly) | 0.36 |
| Gross Profit Margin (Quarterly) | 89.36% |
| Profit Margin (Quarterly) | 11.83% |
| Earnings Yield | 0.25% |
| Operating Earnings Yield | 2.07% |
| Normalized Earnings Yield | 0.8284 |